Latest Pharma and Biotech News
Biotechnology
18 August 2026 US biotech BioMarin Pharmaceutical today announced that it has entered into a definitive agreement to acquire Dutch biotech firm Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.
Today's issue
Refine search
Biotechnology
Japanese drugmaker Ono Pharmaceutical today announced that its Taiwanese subsidiary has received additional approval of Opdivo intravenous Infusion (nivolumab), an anti-PD-1 antibody. 19 August 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted Teva Pharmaceutical Industries' New Drug Application (NDA) for ecopipam and granted it priority review. 19 August 2026
Biotechnology
Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). 19 August 2026
Biotechnology
US pharma companies Merck, known as MSD outside of the USA and Canada, and Moderna today announced positive top-line results from the Phase III INTerpath-001 trial. 19 August 2026
Pharmaceutical
Improving the availability of innovative vaccines in Latin America is a priority for all stakeholders in the health system: policymakers, the pharmaceutical industry responsible for vaccine manufacturing, and patients. 19 August 2026
Pharmaceutical
Danish CNS specialist Lundbeck reported second-quarter 2026 revenue of 6.46 billion kroner ($993.8 million), 4% ahead of consensus and 1% above Jefferies’ estimate. 19 August 2026
Biotechnology
Indian pharma services group Piramal Pharma has completed the acquisition of an incremental 40.67% stake in Yapan Bio, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics, the company announced Tuesday. 19 August 2026
Pharmaceutical
Invesco Mutual Fund has announced the launch of Invesco India Pharma and Healthcare Fund - an open-ended equity scheme investing in pharmaceutical, healthcare and allied sectors. 19 August 2026
Pharmaceutical
US health care tech conglomerate Danaher Corp announced the appointment of Julie Sawyer Montgomery as president and chief executive (CEO) and a member of the board of directors, effective October 1, 2026. 19 August 2026
Biotechnology
USA-based biotech major Amgen is now defending a proposed class action over the cloud breach it disclosed in late July, the first sign that an incident described in a regulatory filing three weeks ago will carry a long legal tail. 19 August 2026
Pharmaceutical
USA-based bioanalysis firm Dash Bio has raised $30 million in a series A round led by Oak HC/FT, money it will spend on a laboratory that hands much of drug safety and efficacy testing to robots. Existing backers Freestyle Capital and Swift Ventures also took part. The round takes total funding at the Waltham, Massachusetts company to $47.5 million. 19 August 2026
Pharmaceutical
USA-based artificial intelligence firm GenBio AI has released AIDO Cell, a virtual cell system that it says can simulate a human cell from DNA and RNA through protein behavior to the whole-cell level, and predict how that cell reacts when a gene is knocked out or a drug is introduced. 19 August 2026
Biotechnology
San Diego, USA-based Zentalis Pharmaceuticals has announced the successful closing of its underwritten public offering, raising around $92.6 million in gross proceeds before deducting fees and expenses. 19 August 2026
Pharmaceutical
In August 2025 talks between the UK government and the pharmaceutical industry over the country's medicines pricing scheme collapsed without agreement. 19 August 2026
Biotechnology
California-based antibody discovery technology provider OmniAb has entered a global collaboration and license agreement with US pharma major Eli Lilly covering a new ion channel drug discovery program, the companies announced Monday. 18 August 2026
Pharmaceutical
USA-based Amylyx Pharmaceuticals saw its shares leap 48% to $31.74 by mid-morning today, after it revealed positive new data for avexitide and plans for a regulatory filing. 18 August 2026
Biotechnology
US biotech BioMarin Pharmaceutical today announced that it has entered into a definitive agreement to acquire Dutch biotech firm Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1. 18 August 2026
Biotechnology
Japanese drugmaker Chugai Pharmaceuticals, which is majority owned by Swiss pharma giant Roche, announced that it has signed an exclusive license agreement with the UK’s GSK for the anti-dengue virus antibody AID351. 18 August 2026
Pharmaceutical
Polish oncology drug developer Ryvu Therapeutics has launched Keelira, a dedicated business offering early clinical development services to biotech and pharma companies seeking to bring oncology programs into Europe, the Krakow-based company announced Tuesday. 18 August 2026
Biotechnology
4C Biomed, a London-headquartered immuno-oncology company with research operations in Israel, has appointed Alan Barge as chief executive officer with immediate effect, the company announced Tuesday. 18 August 2026
All news
Pharmaceutical
UK pharma major GSK is to build a major new global research and development center on the Cambridge Biomedical Campus, moving its UK R&D operations there and closing its long-standing site in Stevenage, Hertfordshire. The company will invest £400 million ($532 million) over three years. 29 July 2026
Pharmaceutical
Medicines regulators across major markets issued a mix of approvals, class-wide safety warnings, a product defect notification and consultation activity over the past week, spanning central nervous system, metabolic, ophthalmology and vaccine areas. 29 July 2026
Pharmaceutical
Privately held, US clinical-stage pharma Saol Therapeutics announced that the US Food and Drug Administration (FDA) has acknowledged the company's resubmission of its New Drug Application (NDA) for SL1009, sodium dichloroacetate (DCA). 29 July 2026
Pharmaceutical
The non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) market in India is entering a new phase, with awareness-driven strategies expected to play a pivotal role in improving diagnosis, treatment access, and patient outcomes. 29 July 2026
Pharmaceutical
UK pharma major GSK reported better-than-expected second-quarter 2026 results, helped by continued growth in Specialty Medicines and Vaccines, as it announced a three-year cost-saving program to fund increased investment in its late-stage pipeline. 28 July 2026
Pharmaceutical
ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading three-drug regimen Biktarvy in the first trial pitting the two directly against each other in patients starting treatment for the first time. The data, from the Phase IIIb VOGUE study, were unveiled this week at the AIDS 2026 conference in Rio de Janeiro, Brazil. 28 July 2026
Biotechnology
MapLight Therapeutics, a US biotech focused on central nervous system disorders, has reported a split verdict from its Phase II ZEPHYR trial in schizophrenia, with one dose of its experimental muscarinic drug hitting the mark and another falling short. 28 July 2026
Pharmaceutical
US obesity specialist Ambrosia Biosciences has strengthened its clinical and scientific ranks, naming cardiometabolic drug developer Linda Shapiro Manning as chief medical officer and adding obesity researcher Randy Seeley to its scientific advisory board. The privately held Boulder, Colorado firm is preparing to move its lead oral candidate into first human trials. 28 July 2026
Biotechnology
UK pharma major GSK today revealed that its licensor Hansoh Pharmaceutical has announced that ARTEMIS-011, its pivotal Phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, met its primary endpoint of progression-free survival (PFS). 28 July 2026
Biotechnology
US late-stage biotech Claris Biotherapies today announced multiple key milestones, including the close of a $118 million Series B financing and key executive and board appointments. 28 July 2026
Biotechnology
USA-based cell therapy company Legend Biotech has named Alan Bash as interim chief executive after Ying Huang stepped down from the role and resigned from the board. 28 July 2026
Biotechnology
US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep apnea (OSA) therapy, Oxnimbi (AD109). 28 July 2026
Biotechnology
Biotech company Capricor Therapeutics faces heightened regulatory uncertainty after US Food and Drug Administration (FDA) reviewers questioned whether its resubmitted Biologics License Application for deramiocel provides substantial evidence of effectiveness in cardiomyopathy in male patients with Duchenne muscular dystrophy. 28 July 2026
Biotechnology
US rare diseases company Sarepta Therapeutics has announced the appointment of Dr Michael Severino as chief executive (CEO), effective July 28, 2026. 28 July 2026
Biotechnology
China is emerging as a global biotechnology innovation hub, but its growing influence is facing political and regulatory scrutiny from the USA. The US policy response reflects concerns around its competitiveness and technological leadership, rather than the country’s scientific capability alone. 28 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) Oncology Center of Excellence has announced three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs. 28 July 2026
Biotechnology
Spruce Biosciences has appointed Dr Adrian Quartel as chief medical officer (CMO), effective immediately. 28 July 2026
Pharmaceutical
Russia plans to focus on the design and production of fundamentally new drugs within the next several years, according to recent statements by Russia’s Prime Minister Mikhail Mishustin. 28 July 2026
Biotechnology
Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed special purpose acquisition company (SPAC) Research Alliance Corporation III. 27 July 2026
Biotechnology
Shares of US biotech Forte Biosciences shot up nearly 40% to $76.40 in early trading, on the news of a takeover bid from Belgo-Dutch immunology specialist argenx. 27 July 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze